文献速递主动脉疾病

基于动脉瘤范围的复杂主动脉瘤开窗与分支腔内修复五年结局

Five-year outcomes of fenestrated and branched endovascular repair of complex aortic aneurysms based on aneurysm extent.
PubMed 文献 · J Vasc Surg · 2024-04-10

单中心回顾性分析436例复杂主动脉瘤患者开窗/分支腔内修复的5年结局,按范围分为I-III型胸腹主动脉瘤组、IV型胸腹主动脉瘤组及近肾/肾旁/肾旁内脏主动脉瘤组,发现范围越大5年生存越低、30天死亡率及二次干预和脊髓缺血发生率越高。

要点

  • I-III型胸腹主动脉瘤组30天死亡率4.5%,显著高于近肾/肾旁/肾旁内脏组的0.4%(P = .01)。
  • 脊髓缺血发生率I-III型组5.3%、IV型组4.3%、近肾/肾旁/肾旁内脏组0.4%,I-III型组显著高于近肾/肾旁/肾旁内脏组(P = .004)。
  • 5年生存近肾/肾旁/肾旁内脏组显著高于I-III型组(P = .01),免于二次干预率亦显著更高(P = .003)。

核心结论

  • 动脉瘤范围越大与5年生存率越低、30天死亡率越高、二次干预及脊髓缺血发生率越高相关。
  • 所有组二次干预发生率均较高,作者认为对接受开窗/分支腔内修复的复杂主动脉瘤患者进行细致随访至关重要。

研究设计与样本

  • 单中心回顾性分析,纳入2012年7月至2023年5月期间接受开窗/分支腔内主动脉修复的复杂主动脉瘤患者436例。
  • 按动脉瘤范围分为3组:组1为I-III型胸腹主动脉瘤131例,组2为IV型胸腹主动脉瘤69例,组3为近肾、肾旁或肾旁内脏主动脉瘤236例。
  • 所有病例均在医生发起的试验性器械豁免方案下治疗,使用患者定制企业制造或现成器械。

主要发现

  • 组1患者较组2和组3显著年轻(69.6 ± 8.7 vs 72.4 ± 7.1 vs 73.2 ± 7.3岁;P < .001),女性比例更高(50.4% vs 21.7% vs 17.8%;P < .001)。
  • 组1主动脉夹层病史显著更常见(26% vs 1.4% vs 0.9%;P < .001),平均动脉瘤直径更大(64.5 vs 60.7 vs 63.2 mm;P = .033)。
  • 技术成功率三组相似(98.5% vs 98.6% vs 98.7%;P > .99)。
  • 30天死亡率组1、组2、组3分别为4.5%、1.4%、0.4%,组1显著高于组3(P = .01)。
  • 脊髓缺血发生率组1、组2、组3分别为5.3%、4.3%、0.4%,组1显著高于组3(P = .004)。

关键数值与推荐

  • 5年生存率组3显著高于组1(P = .01)。
  • 免于二次干预率组3显著高于组1(P = .003)。
  • 5年时免于靶血管不稳定率组间无显著差异,检查的1652条靶血管原发通畅率组间无显著差异。

临床怎么用

  • 作者认为,所有组二次干预发生率均较高,对接受开窗/分支腔内修复的复杂主动脉瘤患者进行细致随访至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to evaluate the 5-year outcomes of fenestrated/branched endovascular aortic repair (F/BEVAR) for the treatment of complex aortic aneurysms stratified by the aneurysm extent. METHODS: Patients with the diagnosis of complex aortic aneurysm, who underwent F/BEVAR at a single center were included in this study and retrospectively analyzed. The cohort was divided according to the aneurysm extent, comparing group 1 (types I-III thoracoabdominal aneurysms [TAAAs]), group 2 (type IV TAAAs), and group 3 (juxtarenal [JRAAs], pararenal [PRAAs], or paravisceral [PVAAs] aortic aneurysms). The primary endpoints were 30-day and 5-year survival. The secondary endpoints were technical success, occurrence of spinal cord ischemia, primary patency of the visceral arteries, freedom from target vessel instability, and secondary interventions. RESULTS: Of 436 patients who underwent F/BEVAR between July 2012 and May 2023, 131 presented with types I to III TAAAs, 69 with type IV TAAAs, and 236 with JRAAs, PRAAs, or PVAAs. All cases were treated under a physician-sponsored investigational device exemption protocol with a patient-specific company-manufactured or off-the-shelf device. Group 1 had significantly younger patients than group 2 or 3 respectively (69.6 ± 8.7 vs 72.4 ± 7.1 vs 73.2 ± 7.3 years; P < .001) and had a higher percentage of females (50.4% vs 21.7% vs 17.8%; P < .001). Prior history of aortic dissection was significantly more common among patients in group 1 (26% vs 1.4% vs 0.9%; P < .001), and mean aneurysm diameter was larger in group 1 (64.5 vs 60.7 vs 63.2 mm; P = .033). Comorbidities were similar between groups, except for coronary artery disease (P < .001) and tobacco use (P = .003), which were less prevalent in group 1. Technical success was similar in the three groups (98.5% vs 98.6% vs 98.7%; P > .99). The 30-day mortality was 4.5%, 1.4%, and 0.4%, in groups 1, 2, and 3, respectively, and was significantly higher in group 1 when compared with group 3 (P = .01). The incidence of spinal cord ischemia was significantly higher in group 1 compared with group 3 (5.3% vs 4.3% vs 0.4%; P = .004). The 5-year survival was significantly higher in group 3 when compared with group 1 (P = .01). Freedom from secondary intervention was significantly higher in group 3 when compared with group 1 (P = .003). At 5 years, there was no significant difference in freedom from target vessel instability between groups or primary patency in the 1652 target vessels examined. CONCLUSIONS: Larger aneurysm extent was associated with lower 5-year survival, higher 30-day mortality, incidence of secondary interventions, and spinal cord ischemia. The prevalence of secondary interventions in all groups makes meticulous follow-up paramount in patients with complex aortic aneurysm treated with F/BEVAR.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Raulli SJ, Gomes VC, Parodi FE, et al. Five-year outcomes of fenestrated and branched endovascular repair of complex aortic aneurysms based on aneurysm extent. J Vasc Surg. 2024. PMID: 38608964. doi:10.1016/j.jvs.2024.04.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。